231 related articles for article (PubMed ID: 24424703)
1. MDMA and heightened cortisol: a neurohormonal perspective on the pregnancy outcomes of mothers used 'Ecstasy' during pregnancy.
Parrott AC; Moore DG; Turner JJ; Goodwin J; Min MO; Singer LT
Hum Psychopharmacol; 2014 Jan; 29(1):1-7. PubMed ID: 24424703
[TBL] [Abstract][Full Text] [Related]
2. Oxytocin, cortisol and 3,4-methylenedioxymethamphetamine: neurohormonal aspects of recreational 'ecstasy'.
Parrott AC
Behav Pharmacol; 2016 Dec; 27(8):649-658. PubMed ID: 27681116
[TBL] [Abstract][Full Text] [Related]
3. MDMA, cortisol, and heightened stress in recreational ecstasy users.
Parrott AC; Montgomery C; Wetherell MA; Downey LA; Stough C; Scholey AB
Behav Pharmacol; 2014 Sep; 25(5-6):458-72. PubMed ID: 25014666
[TBL] [Abstract][Full Text] [Related]
4. Cortisol and 3,4-methylenedioxymethamphetamine: neurohormonal aspects of bioenergetic stress in ecstasy users.
Parrott AC
Neuropsychobiology; 2009; 60(3-4):148-58. PubMed ID: 19893332
[TBL] [Abstract][Full Text] [Related]
5. Hypothalamic-pituitary-adrenal axis responses to stress in subjects with 3,4-methylenedioxy-methamphetamine ('ecstasy') use history: correlation with dopamine receptor sensitivity.
Gerra G; Bassignana S; Zaimovic A; Moi G; Bussandri M; Caccavari R; Brambilla F; Molina E
Psychiatry Res; 2003 Sep; 120(2):115-24. PubMed ID: 14527643
[TBL] [Abstract][Full Text] [Related]
6. Psychiatric profiles of mothers who take Ecstasy/MDMA during pregnancy: reduced depression 1 year after giving birth and quitting Ecstasy.
Turner JJ; Parrott AC; Goodwin J; Moore DG; Fulton S; Min MO; Singer LT
J Psychopharmacol; 2014 Jan; 28(1):55-61. PubMed ID: 24327452
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetic studies of change in cortisol on ecstasy (MDMA) consumption.
Wolff K; Tsapakis EM; Pariante CM; Kerwin RW; Forsling ML; Aitchison KJ
J Psychopharmacol; 2012 Mar; 26(3):419-28. PubMed ID: 21969106
[TBL] [Abstract][Full Text] [Related]
8. Basal functioning of the hypothalamic-pituitary-adrenal (HPA) axis and psychological distress in recreational ecstasy polydrug users.
Wetherell MA; Montgomery C
Psychopharmacology (Berl); 2014 Apr; 231(7):1365-75. PubMed ID: 24190587
[TBL] [Abstract][Full Text] [Related]
9. MDMA (3,4-Methylenedioxymethamphetamine) or ecstasy: the neuropsychobiological implications of taking it at dances and raves.
Parrott AC
Neuropsychobiology; 2004; 50(4):329-35. PubMed ID: 15539865
[TBL] [Abstract][Full Text] [Related]
10. Neurobehavioral outcomes of infants exposed to MDMA (Ecstasy) and other recreational drugs during pregnancy.
Singer LT; Moore DG; Fulton S; Goodwin J; Turner JJ; Min MO; Parrott AC
Neurotoxicol Teratol; 2012; 34(3):303-10. PubMed ID: 22387807
[TBL] [Abstract][Full Text] [Related]
11. Dance clubbing on MDMA and during abstinence from Ecstasy/MDMA: prospective neuroendocrine and psychobiological changes.
Parrott AC; Lock J; Conner AC; Kissling C; Thome J
Neuropsychobiology; 2008; 57(4):165-80. PubMed ID: 18654086
[TBL] [Abstract][Full Text] [Related]
12. MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress.
Parrott AC
J Psychopharmacol; 2006 Mar; 20(2):147-63. PubMed ID: 16510474
[TBL] [Abstract][Full Text] [Related]
13. Increased cortisol levels in hair of recent Ecstasy/MDMA users.
Parrott AC; Sands HR; Jones L; Clow A; Evans P; Downey LA; Stalder T
Eur Neuropsychopharmacol; 2014 Mar; 24(3):369-74. PubMed ID: 24333019
[TBL] [Abstract][Full Text] [Related]
14. Reduced memory skills and increased hair cortisol levels in recent Ecstasy/MDMA users: significant but independent neurocognitive and neurohormonal deficits.
Downey LA; Sands H; Jones L; Clow A; Evans P; Stalder T; Parrott AC
Hum Psychopharmacol; 2015 May; 30(3):199-207. PubMed ID: 25900184
[TBL] [Abstract][Full Text] [Related]
15. Human psychobiology of MDMA or 'Ecstasy': an overview of 25 years of empirical research.
Parrott AC
Hum Psychopharmacol; 2013 Jul; 28(4):289-307. PubMed ID: 23881877
[TBL] [Abstract][Full Text] [Related]
16. The recreational drug ecstasy disrupts the hypothalamic-pituitary-gonadal reproductive axis in adult male rats.
Dickerson SM; Walker DM; Reveron ME; Duvauchelle CL; Gore AC
Neuroendocrinology; 2008; 88(2):95-102. PubMed ID: 18309234
[TBL] [Abstract][Full Text] [Related]
17. MDMA interactions with pharmaceuticals and drugs of abuse.
Papaseit E; Pérez-Mañá C; Torrens M; Farré A; Poyatos L; Hladun O; Sanvisens A; Muga R; Farré M
Expert Opin Drug Metab Toxicol; 2020 May; 16(5):357-369. PubMed ID: 32228243
[No Abstract] [Full Text] [Related]
18. Of mice and men on MDMA: A translational comparison of the neuropsychobiological effects of 3,4-methylenedioxymethamphetamine ('Ecstasy').
Aguilar MA; García-Pardo MP; Parrott AC
Brain Res; 2020 Jan; 1727():146556. PubMed ID: 31734398
[TBL] [Abstract][Full Text] [Related]
19. (+/-)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: clinical studies.
McCann UD; Eligulashvili V; Ricaurte GA
Neuropsychobiology; 2000; 42(1):11-6. PubMed ID: 10867551
[TBL] [Abstract][Full Text] [Related]
20. In abstinent MDMA users the cortisol awakening response is off-set but associated with prefrontal serotonin transporter binding as in non-users.
Frokjaer VG; Erritzoe D; Holst KK; Madsen KS; Fisher PM; Madsen J; Svarer C; Knudsen GM
Int J Neuropsychopharmacol; 2014 Aug; 17(8):1119-28. PubMed ID: 24524290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
